FDA imposes partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000

FDA announced a partial clinical hold on Biohaven's ion channel program, affecting the epilepsy trial of the experimental drug BHV-7000.

The hold was issued after the agency requested additional preclinical safety data, leading to a pause in patient enrollment and dosing.

Biohaven said it will cooperate with the FDA to supply the needed information and hopes to restart the study once the concerns are resolved.

The action highlights the regulatory challenges facing novel ion-channel therapies and could push back the timeline for BHV-7000's development.